Overview

A Study of Abemaciclib (LY2835219) in Women With HR+, HER2+ Locally Advanced or Metastatic Breast Cancer

Status:
Active, not recruiting

Trial end date:
2022-02-28

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the effectiveness of abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus physicians choice standard of care chemotherapy in women with hormone receptor positive (HR+), human epidermal growth factor receptor 2 positive (HER2+) locally advanced or metastatic breast cancer after prior exposure to at least two HER2-directed therapies for advanced disease.

Phase:

Phase 2

Details

Lead Sponsor:

Eli Lilly and Company

Treatments:

Estradiol
Fulvestrant
Trastuzumab